z-logo
open-access-imgOpen Access
Mesenchymal Cell Reprogramming in Experimental MPLW515L Mouse Model of Myelofibrosis
Author(s) -
Ying Han,
Lanzhu Yue,
Max Wei,
Xiubao Ren,
Zhang Shao,
Ling Zhang,
Ross L. Levine,
Pearlie K. EplingBurnette
Publication year - 2017
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0166014
Subject(s) - mesenchymal stem cell , myelofibrosis , cancer research , bone marrow , stromal cell , biology , fibrosis , immunology , microbiology and biotechnology , medicine , pathology
Myelofibrosis is an indicator of poor prognosis in myeloproliferative neoplasms (MPNs), but the precise mechanism(s) contributing to extracellular matrix remodeling and collagen deposition in the bone marrow (BM) niche remains unanswered. In this study, we isolated mesenchymal stromal cells (MSCs) from mice transplanted with wild-type thrombopoietin receptor ( MPL WT ) and MPL W515L retroviral-transduced bone marrow. Using MSCs derived from MPL W515 -transplant recipients, excessive collagen deposition was maintained in the absence of the virus and neoplastic hematopoietic cells suggested that the MSCs were reprogrammed in vivo . TGFβ production by malignant megakaryocytes plays a definitive role promoting myelofibrosis in MPNs. However, TGFβ was equally expressed by MSCs derived from MPL WT and MPL W515L expressing mice and the addition of neutralizing anti-TGFβ antibody only partially reduced collagen secretion in vitro . Interestingly, profibrotic MSCs displayed increased levels of pSmad3 and pSTAT3 suggesting that inflammatory mediators cooperating with the TGFβ-receptor signaling may maintain the aberrant phenotype ex vivo . FGFb is a known suppressor of TGFβ signaling. Reduced collagen deposition by FGFb-treated MSCs derived from MPL W515L mice suggests that the activating pathway is vulnerable to this suppressive mediator. Therefore, our findings have implications for the future investigation of therapies to reverse fibrosis in MPNs.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here